Cooper Companies (NYSE:COO – Get Rating) had its price target trimmed by KeyCorp from $459.00 to $414.00 in a report published on Wednesday, The Fly reports. The firm currently has an overweight rating on the medical device company’s stock. KeyCorp also issued estimates for Cooper Companies’ Q2 2022 earnings at $3.34 EPS, Q3 2022 earnings at $3.55 EPS, Q4 2022 earnings at $3.58 EPS, FY2022 earnings at $13.70 EPS, FY2023 earnings at $15.40 EPS and FY2024 earnings at $17.50 EPS.
Several other equities analysts have also recently weighed in on COO. Stephens boosted their price objective on Cooper Companies from $430.00 to $500.00 and gave the stock an overweight rating in a research report on Monday, March 7th. Needham & Company LLC began coverage on Cooper Companies in a research report on Friday, April 8th. They set a hold rating for the company. StockNews.com began coverage on Cooper Companies in a research report on Thursday, March 31st. They set a hold rating for the company. Citigroup raised Cooper Companies from a neutral rating to a buy rating and cut their price target for the company from $460.00 to $405.00 in a report on Tuesday, May 17th. Finally, Piper Sandler upped their price target on Cooper Companies from $490.00 to $500.00 in a report on Friday, March 4th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of Buy and a consensus target price of $448.44.
COO opened at $352.17 on Wednesday. The company has a market cap of $17.36 billion, a PE ratio of 18.68, a price-to-earnings-growth ratio of 2.19 and a beta of 0.90. The stock has a 50-day moving average of $378.40 and a 200-day moving average of $393.26. Cooper Companies has a 52-week low of $309.43 and a 52-week high of $463.59. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.67 and a current ratio of 1.02.
In other Cooper Companies news, SVP Agostino Ricupati sold 5,607 shares of Cooper Companies stock in a transaction dated Friday, March 18th. The stock was sold at an average price of $421.51, for a total value of $2,363,406.57. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Robert S. Weiss sold 13,039 shares of the firm’s stock in a transaction dated Tuesday, March 29th. The shares were sold at an average price of $415.24, for a total value of $5,414,314.36. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 19,646 shares of company stock worth $8,195,614. 1.70% of the stock is owned by corporate insiders.
Several large investors have recently modified their holdings of COO. Riverview Trust Co acquired a new position in Cooper Companies during the first quarter valued at approximately $29,000. Liberty Wealth Management LLC boosted its stake in shares of Cooper Companies by 1,340.0% during the third quarter. Liberty Wealth Management LLC now owns 72 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 67 shares in the last quarter. PrairieView Partners LLC bought a new position in shares of Cooper Companies during the fourth quarter worth about $33,000. O Shaughnessy Asset Management LLC raised its position in shares of Cooper Companies by 66.7% during the third quarter. O Shaughnessy Asset Management LLC now owns 85 shares of the medical device company’s stock worth $35,000 after acquiring an additional 34 shares during the last quarter. Finally, Trust Co. of Vermont bought a new stake in Cooper Companies in the fourth quarter worth approximately $36,000. Institutional investors own 98.38% of the company’s stock.
About Cooper Companies (Get Rating)
The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific.
- Get a free copy of the StockNews.com research report on Cooper Companies (COO)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.